HC Wainwright keeps USD 220.00 target for Insmed stock

Published on 10/20/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 425.49 million, up 296.10 percent year over year. Insmed stock costs EUR 85.12 on October 20, 2026.

Analyst target and reporting date

HC Wainwright maintained a USD 220.00 target and Buy rating for Insmed on October 12, 2026.
Second-quarter revenue reached USD 425.49 million, up 296.10 percent from the prior year.
Insmed stock costs EUR 85.12 at Lang & Schwarz on October 20, 2026 at 9:23 p.m. CEST.
Insmed is scheduled to report third-quarter 2026 results on October 29, 2026.

INSM, US4576693075, Illustration mit AI erstellt.

HC Wainwright maintained a Buy rating and a USD 220.00 price target for Insmed on October 12, 2026, according to MarketBeat. The target stands 129.96 percent above the USD 95.67 intraday Nasdaq price at 3:27 p.m. ET on October 20, 2026. Insmed was trading at EUR 85.12 at Lang & Schwarz on October 20, 2026 at 9:23 p.m. CEST.

Revenue sets the operating backdrop

For the quarter ended June 30, 2026, Insmed reported revenue of USD 425.49 million, up 296.10 percent from USD 107.42 million a year earlier, while GAAP net loss narrowed to USD 13.24 million. Markets Insider reported the quarterly figures and the year-over-year comparison.

The result also included adjusted earnings per share of negative USD 0.06 against a negative USD 0.67 consensus estimate, a USD 0.61 improvement versus expectations. That comparison remains central to the analyst case because revenue growth and narrowing losses are moving together in the latest reported quarter.

What does the target imply?

The USD 220.00 target is more than twice the October 20 Nasdaq price, but the company still carries a negative price-to-earnings ratio of 23.28. Market capitalization stood at USD 20.9 billion, while the 52-week range ran from USD 90.39 to USD 212.75 as of October 20, 2026.

October 29 is the next date

Insmed's investor-relations calendar lists third-quarter 2026 financial results for October 29, 2026, with an 8:00 a.m. EDT release time, according to Insmed. The date will provide the next reported measure of commercial progress after the second-quarter revenue increase.

Stock position and next test

Insmed's Nasdaq listing gives investors a home-market price of USD 95.67 at 3:27 p.m. ET on October 20, 2026, while the euro quote reflects the German trading perspective. The next results release will put the USD 220.00 analyst target alongside updated revenue, earnings and cash-flow figures.

Euro quote after hours

Insmed was trading at EUR 85.12 at Lang & Schwarz on October 20, 2026 at 9:23 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Insmed stock.